Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia

8 Nov 2021

Abstract excerpt

BACKGROUND: To determine the effect of genetic polymorphism of drug transporters on the efficacy of treatment with Rosuvastatin, Atorvastatin and Simvastatin in patients with hyperlipidemia. METHODS: The study consists of 180 patients, aged 40-75 years, with hyperlipidemia. All patients were divided into two equal groups: patients with different SLCO1B1 (521CC, 521CT and 521TT) and MDR1 (3435CC, 3435TC and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Transport and Resistance Mechanisms
Share to Lipoproteins and Cardiovascular Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34749751
DOI: 10.1186/s12944-021-01586-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemiaPMID 34749751Read ↗

Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.Semantic proximity Read ↗

The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins.Semantic proximity Read ↗

The lipid-lowering efficacy of rosuvastatin is associated with variations in SLCO1B1: a 12-month prospective cohort study.Semantic proximity Read ↗

An update on efflux and uptake transporters as determinants of statin response.Semantic proximity Read ↗

Associations between four polymorphisms of the SLCO1B1 and effectiveness of the statins: a meta-analysis.Semantic proximity Read ↗

Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects.Semantic proximity Read ↗

Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population.Semantic proximity Read ↗

Genetic contribution to lipid target achievement with statin therapy: a prospective study.Semantic proximity Read ↗

Meta-Analysis of the SLCO1B1 c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins.Semantic proximity Read ↗

Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin.Semantic proximity Read ↗

SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians.Semantic proximity Read ↗

SLCO1B1 and ABCB1 variants synergistically influence the atorvastatin treatment response in South Indian coronary artery disease patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.